Pfizer closed its takeover of obesity biotech Metsera after a contested bidding period, securing Metsera’s pipeline including a fast‑acting amylin analog alongside a long‑acting GLP‑1. The deal capped a high‑stakes fight that drew interest from Novo Nordisk and underscored pharma appetite for obesity/metabolic assets. The acquisition gives Pfizer immediate product candidates and bolsters its obesity portfolio at a time of intense competition in the metabolic drugs market.